MAPLE

Double-blind short term pre-surgical study to assess the molecular antiproliferative predictors of lapatinib’s effects in breast cancer.

Disease site: Breast cancer

Treatment Modality: Other

Status: Closed

Trial details

The aim of the MAPLE study is to evaluate changes in biological characteristics, using a known molecular marker responsible for tumour growth (Ki67). Lapatinib has shown promising anti-tumour activity in breast cancer and targeting this drug to the most appropriate subset of breast cancer patients in the future will depend on a full understanding of the molecular determinants of response.

Women presenting with a breast lump were considered for inclusion in the MAPLE study. Following confirmation of diagnosis and consent, research samples taken at diagnostic biopsy were compared with those taken at main surgery and following a two week course of treatment (lapatinib or lapatinib-placebo in a 3:1 ratio). The trial opened in July 2007 and recruited 121 patients. 

Chief Investigator: Professor Stephen Johnston, Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead:Professor Judith Bliss

Trial management contact: [email protected]

ISRCTN: 68509377

Sponsor: The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research

Funding: Cancer Research UK (CRUKE/06/039) & GlaxoSmithKline

Publications and presentations

Evans A, Leary A, Johnston S, A'Hern R, Bliss JM, Hills M, Harper-Wynne C, Bundred N, Coombes G, Sahoo R, Detre S, Smith I, Dowsett M. Lapatinib has antiproliferative effects in both HER2 positive (+) and HER2 negative (-) breast cancer (BC): results from the MAPLE short-term pre-surgical trial (CRUK E/06/039). Proc of AACR Annual Meeting 2012:#LB222

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story